Nov 9, 2022 6:45 am EST Kiora Pharmaceuticals Provides 3rd Quarter 2022 Business and Financial Update; Dosing of KIO-301 in Phase 1 Trial for Retinitis Pigmentosa to Begin Before Year's End
Oct 17, 2022 8:00 am EDT Kiora Pharmaceuticals Announces Publication of Phase 1 Trial Results for KIO-100 as a Treatment for Ocular Inflammatory Disease
Sep 28, 2022 9:28 am EDT Battling Blindness: Virtual Investor Event on Treatments for Retinitis Pigmentosa to Be Held Oct 19; Panelists include Kiora Pharmaceuticals, Foundation Fighting Blindness, and Retinal Surgeon Christine Kay, M.D.
Sep 15, 2022 12:23 pm EDT Kiora Pharmaceuticals To Participate in the Ladenburg Thalmann 2022 Healthcare Conference
Sep 13, 2022 6:45 am EDT Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance
Aug 12, 2022 6:45 am EDT Kiora Pharmaceuticals Reports First Half 2022 Business Update and Financial Results
Aug 9, 2022 11:00 am EDT Kiora Pharmaceuticals To Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference; Online Presentation Will Be Available August 17, 2022 at 7:00 am EST